These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31478913)

  • 1. Clinical testing should be individualized, not based on populations.
    Walt DR
    J Clin Invest; 2019 Sep; 129(9):3472-3473. PubMed ID: 31478913
    [No Abstract]   [Full Text] [Related]  

  • 2. New cancer blood test developed.
    Burki TK
    Lancet Oncol; 2018 Mar; 19(3):e140. PubMed ID: 29395866
    [No Abstract]   [Full Text] [Related]  

  • 3. Early solid tumor diagnosis through next-generation sequencing of cell-free DNA.
    Ziogas DE; Kyrochristos ID; Lykoudis EG; Roukos DH
    Biomark Med; 2018 Nov; 12(11):1197-1201. PubMed ID: 30379093
    [No Abstract]   [Full Text] [Related]  

  • 4. Early detection and monitoring of cancer in liquid biopsy: advances and challenges.
    Xue VW; Wong CSC; Cho WCS
    Expert Rev Mol Diagn; 2019 Apr; 19(4):273-276. PubMed ID: 30760042
    [No Abstract]   [Full Text] [Related]  

  • 5. Circulating tumor DNA-From bench to bedside.
    Lim JSJ; Janku F; Yap TA
    Curr Probl Cancer; 2017; 41(3):212-221. PubMed ID: 28416241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.
    Khagi Y; Goodman AM; Daniels GA; Patel SP; Sacco AG; Randall JM; Bazhenova LA; Kurzrock R
    Clin Cancer Res; 2017 Oct; 23(19):5729-5736. PubMed ID: 28972084
    [No Abstract]   [Full Text] [Related]  

  • 7. Blood-based tumour mutational burden analysis in NSCLC.
    Das M
    Lancet Oncol; 2018 Sep; 19(9):e446. PubMed ID: 30122616
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies.
    Abbou SD; Shulman DS; DuBois SG; Crompton BD
    Pediatr Blood Cancer; 2019 May; 66(5):e27595. PubMed ID: 30614191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic profiling of cancer with circulating tumor DNA analysis.
    Lu L; Bi J; Bao L
    J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility versus futility: a tipping point for liquid biopsies in bladder cancer.
    Kouba E; Cheng L
    Future Oncol; 2019 Nov; 15(33):3751-3753. PubMed ID: 31651200
    [No Abstract]   [Full Text] [Related]  

  • 11. Utilizing circulating tumour DNA in radiation oncology.
    Rostami A; Bratman SV
    Radiother Oncol; 2017 Sep; 124(3):357-364. PubMed ID: 28735685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liquid Biopsy and Lung Cancer.
    Pisapia P; Malapelle U; Troncone G
    Acta Cytol; 2019; 63(6):489-496. PubMed ID: 30566947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor DNA
    Sun X; Li H; Sun M; Yuan Y; Sun L
    Future Oncol; 2019 Oct; 15(30):3513-3525. PubMed ID: 31578881
    [No Abstract]   [Full Text] [Related]  

  • 14. Sequencing Circulating Cell-Free DNA: The Potential to Refine Precision Cancer Medicine.
    Tie J; Gibbs P
    Clin Chem; 2016 Jun; 62(6):796-8. PubMed ID: 27117467
    [No Abstract]   [Full Text] [Related]  

  • 15. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
    Jovelet C; Ileana E; Le Deley MC; Motté N; Rosellini S; Romero A; Lefebvre C; Pedrero M; Pata-Merci N; Droin N; Deloger M; Massard C; Hollebecque A; Ferté C; Boichard A; Postel-Vinay S; Ngo-Camus M; De Baere T; Vielh P; Scoazec JY; Vassal G; Eggermont A; André F; Soria JC; Lacroix L
    Clin Cancer Res; 2016 Jun; 22(12):2960-8. PubMed ID: 26758560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling.
    Scherer F
    Recent Results Cancer Res; 2020; 215():213-230. PubMed ID: 31605231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Cell-Free DNA and Cancer Therapy Monitoring: Methods and Potential.
    Gahan PB
    Methods Mol Biol; 2019; 1909():31-46. PubMed ID: 30580421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Throughput and Sensitive Quantification of Circulating Tumor DNA by Microfluidic-Based Multiplex PCR and Next-Generation Sequencing.
    Guan Y; Mayba O; Sandmann T; Lu S; Choi Y; Darbonne WC; Leveque V; Ryner L; Humke E; Tam NWR; Sujathasarma S; Cheung A; Bourgon R; Lackner MR; Wang Y
    J Mol Diagn; 2017 Nov; 19(6):921-932. PubMed ID: 28867605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
    Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.